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Abstract : Long-term cognitive effects following acute lymphoblastic leukemia treat-
ment have been reported for Caucasians; however, these data remain unclear for 
other ethnicities and the treatment of other cancers.  Here, we assessed cognitive 
function in Japanese childhood cancer survivors.  This study enrolled 53 Japanese 
survivors of childhood cancer （mean age, 9.5 years; 36 boys and 17 girls）.  We 
evaluated performance-based cognitive function using the Wechsler Intelligence 
Scale for Children-Fourth Edition （WISC-Ⅳ）.  Deviation intelligence quotients 
（IQ） for verbal comprehension （VC）, perceptual reasoning （PR）, processing speed 
（PS）, and working memory （WM） were compared with the standardized mean 
and standard deviation （SD; 100 and 15, respectively）.  We classified patients 
into three groups depending on the cumulative methotrexate （MTX） dose （none, 
1–19 g / m2, and＞20 g / m2）.  Full-scale IQ was within normal range at 104.8 （SD, 
12.9）, although there were signicant differences among the four WISC–Ⅳ index 
scores （P＜0.001）.  The PS score （97.1±15.5） was signicantly lower than the VC 
（107.2±15.8） and PR （105.3±14.2） scores （both P＜0.005）.  WM performance 
decreased in an MTX dose-dependent manner （107.8, 102.6, and 96.5 for none, 
1–19 g / m2, and higher than 20 g / m2, respectively; P=0.05）.  Japanese childhood 
cancer survivors, including those in the non-MTX group, demonstrated signicant 
PS impairment.  High-dose MTX treatment might be associated with neurocognitive 
deciencies, particularly in WM.  Although current treatments are associated with 
high cure rates, future research and interventions are required to improve cognitive 
function in these patients.
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Introduction
　Treatment for childhood cancer has improved dramatically in recent years, resulting in 
estimated survival rates higher than 70％1）. Nevertheless, childhood cancer survivors, especially 
those with acute lymphoblastic leukemia （ALL）, are at risk of late, adverse, neurocognitive 
effects, including difficulties with attention, visual-motor function, processing speed, and working 
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memory2，3）. Risk factors for neurocognitive difficulties include the need for greater intensity of 
cranial radiation therapy （CRT）4-6）, high-dose methotrexate （MTX） treatment6，7）, and younger 
age at diagnosis8，9）. While late neurocognitive adverse effects have been reported in childhood 
ALL especially for Caucasians, there has been a limited focus on other types of childhood 
cancer and ethnicities.  To our knowledge, no published reports have examined the effects of 
treatment in Japanese patients with childhood cancer.  This study aimed to assess cognitive 
function in Japanese patients with childhood cancer whose conditions remained stable after acute-
phase treatment.
Patients and Methods
1.  Participants （Table 1）
　This study was part of a larger cross-sectional survey of cognitive function following treatment 
for childhood cancer.  Participants were 53 Japanese survivors of childhood cancer （mean 
age, 9.5±3.2 ［range, 5–16］ years; 36 boys and 17 girls; ALL, n=37; acute myeloid leukemia 
［AML］, n=6; chronic myeloid leukemia ［CML］, n=1; lymphoma, n=2; and solid tumors, n=7）, 
recruited from the outpatient pediatric clinic of Showa University Fujigaoka Hospital.  All 
participants completed acute-phase treatment and remained stable with no history of neurological 
disease or injury.  None of the patients had a history of premorbid learning disabilities or 
other developmental conditions before the initial treatment.  The treatment protocols varied 
by participant, but mostly included systemic corticosteroid, systemic MTX, and / or cytarabine 
administration.  Four patients received CRT.  Written informed consent was obtained from the 
parents, while the children agreed to be interviewed and to undergo the assessment.  The study 
was approved by the Ethics Committee of Showa University Fujigaoka Hospital, Institutional 
Review Board （Permit Number: 2016037） and was conducted following the provisions of the 
Declaration of Helsinki.
Table 1.  Patient characteristics
Number of patients 53
Sex: male / female 36 / 17
Age: median （range） 9.5years （5–16 years）
Day of examination post hospital dis-
charge: median （range） 1,369 days （62–4,815 days）
ALL / AML / CML / ML / ST 37 / 6 / 1 / 2 / 7 
Cranial irradiation（＋ / -） 4 / 49
HD-MTX（＋ / -） 39 / 14
IT（＋ / -） 46 / 7
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CML: 
chronic myeloid leukemia, ML: malignant lymphoma, ST: solid tumor, 
Cranial irradiation: cranial irradiation with 12 to 24grays,
HD-MTX: high-dose methotrexate （10 g / m2 or 20 g / m2）,
IT: intrathecal therapy（MTX, cytarabine, and steroids）.
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2 Assessments
　We evaluated performance-based cognitive function using the Wechsler Intelligence Scale 
for Children–Fourth Edition （WISC-Ⅳ）.  Examiners were Master-level licensed psychologists 
qualified and experienced in administering the WISC-Ⅳ.  The WISC-Ⅳ provides a full-
scale intelligence quotient （FSIQ） score, as well as four composite Index Scores, and has a 
standardized mean and standard deviation （SD） of 100 and 15, respectively.  The Index Scores 
for four domains were calculated based on the following subtests; Verbal Comprehension 
（VC; composed of the Vocabulary and Similarities subtests）, Perceptual Reasoning （PR; Block 
Design and Matrix Reasoning subtests）, Working Memory （WM; Digit Span and Letter-
Number Sequencing subtests）, and Processing Speed （PS; Coding and Symbol Search subtests）. 
All scaled scores and Index Scores were derived from the raw scores based on the Japanese 
standardization sample data.  The WISC-V was not released in Japan at the time of data 
collection.
3. Data analysis
　All data were analyzed using the Statistical Package for the Social Sciences （IBM Corp., 
Armonk, NY）.  The box plot revealed no extreme outliers, and the WISC-Ⅳ FSIQ and all 
WISC-Ⅳ Index Scores were normally distributed.  Repeated-measures analysis of variance was 
performed to examine differences among the cognitive performance domains using the four 
WISC-Ⅳ Index Scores as intra-individual factors.  Bonferroni post-hoc pairwise comparisons were 
also conducted, while Spearman’s correlations were used to examine the relationships between 
age at diagnosis, counts of intrathecal therapy （IT）, counts of high-dose MTX therapy, counts of 
cytarabine therapy, days between complete response and testing, and cognitive performance.  We 
divided the patients in three groups depending on the cumulative MTX dose （none, moderate 
［1–19 g / m2］, and high ［higher than 20 g / m2］） to explore associations between the cumulative 
MTX dose and cognitive function.  Finally, we performed subgroup analysis of the high, 
cumulative MTX-dose group because previous studies indicated that MTX treatment could affect 
cognitive function.  To avoid type I error due to multiple comparisons, the significance level for 
all analyses was set to 0.005 （two-tailed）.
Results
　The FSIQ was 104.8±15.5, which was within the age-matched average range for the general 
population.  Meanwhile, there were significant differences among the four WISC-Ⅳ Index 
Scores （F［3,156］=7.893, P＜0.001）.  Post-hoc analysis revealed the PS score （97.1±15.5） to 
be significantly lower than the VC （107.2±15.8） and PR （105.3±14.2） scores （each P＜0.005, 
Bonferroni corrected） （Fig. 1）.  In addition, although age at diagnosis, counts of IT, counts of 
cytarabine therapy, and days between complete response and testing were not associated with 
a cognitive function domain, the counts of high-dose MTX therapy were significantly correlated 
with poor WM performance （r=-0.342, P=0.013） （Table 2）.  Accordingly, we observed a 
decreasing trend in WM performance as the MTX dose increased; WM scores for none, 
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moderate, and high-dose groups were 107.8, 102.6, and 96.5, respectively （P=0.05）.  Post-hoc 
analysis revealed a significantly lower WM score in the high-MTX group （96.5） than in the non-
MTX group （107.8; P＜0.05, Bonferroni corrected） （Fig. 2）, while the PS score was decreased in 
all groups including the non-MTX group （including patients with AML, CML, and solid tumors） 
（Fig. 3）.  Finally, sub-group analysis in the high MTX group revealed a significantly lower WM 
Fig. 1.   Cognitive performance （Wechsler Intelligence Scale for Children–
Fourth Edition） of childhood cancer survivors
IQ: intelligence quotient, VC: verbal comprehension, PR: perceptual 
reasoning, WM: working memory, PS: processing speed, ANOVA: 
analysis of variance. 
Table 2.  Relationship between cognitive function and each factor
　 FSIQ VC PR WM PS VC-WM
Age 
.069 .124 .039 -.124 -.195 .217
.621 .375 .779 .375 .162 .119
IT
-.135 -.032 -.157 -.198 .054 .113
.339 .824 .267 .160 .706 .424
HD-MTX
.008 .186 -.086 -.342 .148 .433
.958 .186 .543 .013 .294 .001
AraC
-.171 -.201 -.239 .035 -.063 -.242
.225 .154 .088 .805 .656 .084
Day of examination 
post hospital discharge
.113 .120 .008 .076 -.066 .105
.422 .391 .955 .590 .638 .453
FSIQ: full scale intelligence quotient, VC: verbal comprehension, PR: perceptual reasoning, WM: 
working memory, PS: processing speed, IT: intrathecal therapy （MTX, cytarabine, and steroids）, HD-
MTX: high-dose methotrexate （10 g /m2 or 20 g / m2）, AraC: cytarabine is a chemotherapy drug.
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score （96.5） than the VC （109.6） and PR （106.1） scores （P<0.01 and P<0.05, respectively, 
Bonferroni corrected） （Fig. 4）.
Discussion
　The childhood cancer survivors studied herein had intact FSIQ compared with the population 
Fig. 2.  Histogram of total methotrexate （MTX） dose
Fig. 3.   Cognitive performance （Wechsler Intelligence Scale for Children–Fourth 
Edition） impairment by methotrexate （MTX） dose 
IQ: intelligence quotient, VC: verbal comprehension, PR: perceptual 
reasoning, WM: working memory, PS: processing speed, ANOVA: 
analysis of variance.
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normative data; however, they showed significant PS deficits on the group level.  Several 
previous studies found that although general intellectual ability in ALL survivors is not affected 
by chemotherapy alone, their PS is significantly lower than that of comparison peers10-12）, and this 
is supported by our findings.  Generally, central nervous system （CNS）-directed chemotherapy, 
such as CRT and high-dose MTX, is required for ALL and it is well known that patients with 
ALL may have cognitive dysfunction13）. In the current study, PS was also decreased in the other 
types of cancer examined.  To our knowledge, this is the first study investigating the association 
between cognitive function and childhood cancer in patients not receiving CNS-directed 
chemotherapy.  Interestingly, our study patients with childhood cancer who did not receive high-
dose MTX （i.e., those with AML, CML, and solid tumors） also had decreased PS.  While little 
is known about the association between PS impairment and childhood cancer treatment other 
than high-dose MTX, depression, the effects of long-term hospitalization, and parenting stress 
could play a role.  Indeed, there is some evidence from adult cancer survivors that perceived 
depressive symptoms might strongly affect cognitive performance14）, while Patel et al 15）. reported 
an association between PS impairment and parenting stress.  
　In the current study, a negative correlation was found between MTX dose and WM 
performance.  In support of this finding, previous meta-analysis data indicated that PS and WM 
are significantly impaired in childhood cancer survivors16）. In addition, although some studies 
Fig. 4.   Cognitive performance （Wechsler Intelligence Scale for Children–Fourth 
Edition） of childhood cancer survivors in the high-methotrexate group 
（＞20 g / m2）
IQ: intelligence quotient, VC: verbal comprehension, PR: perceptual 
reasoning, WM: working memory, PS: processing speed, ANOVA: analysis of 
variance.
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found no association between MTX dose and neurocognitive outcome7，17）, other investigators 
reported that childhood ALL survivors who received high-dose intravenous MTX had a greater 
degree of neurocognitive problems than those administered low-dose MTX18-20）, as indicated by 
the present study results.  All previous studies were conducted with Caucasian samples, and our 
study is the first to confirm the same results in an Asian population.
　Recently, a cognitive and problem-solving program was implemented for leukemia and brain 
tumor survivors21，22）. Hardy et al 22）. reported good feasibility and acceptability of the program 
with signicant increases in WM and parent reports of decreased attention problems following 
the 12-week program, while Moore et al 23）. reported that early mathematics intervention can 
prevent a decline in mathematical ability and cognitive function in patients with childhood ALL. 
Accordingly, we plan to implement an early intervention involving a computerized cognitive 
training program for patients with childhood cancer undergoing chemotherapy.
　Although age at diagnosis, counts of IT, counts of cytarabine therapy, and days between 
complete response and testing were not associated with any cognitive function domain, the 
counts of high-dose MTX therapy were significantly correlated with poor WM performance. 
The patients who received high-dose MTX therapy were almost all ALL patients and were 
hospitalized for approximately 1 year, whereas the hospitalization of other patients varied 
between 6 months and 1 year.  There was no significant difference in the age at first onset with 
or without high-dose MTX.  Based on the above findings, long-term hospitalization is considered 
a confounding factor related to the WM decrease in the high-dose MTX administration group.
　In this study, the general comparison was difficult because only a small number of the patients 
who were hospitalized for approximately 1 year in the control group did not receive high-dose 
MTX.  Accordingly, accumulating a larger number of cases is necessary in the future because 
the effects of long-term hospitalization in childhood and high-dose MTX therapy should also be 
considered.
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